Literature DB >> 11902587

The case for population-based screening for colorectal cancer.

Robert E Schoen1.   

Abstract

Screening for colorectal cancer is commanding increasing attention. Other cancer screening programmes have been a part of public consciousness for some time, but, until recently, colorectal cancer screening has remained in the background. Fuelled by new research, market opportunities and increased recognition of individual risk, screening for colorectal cancer is becoming a recommended procedure, but controversy about how best to implement widespread screening remains.

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 11902587     DOI： 10.1038/nrc705

Source DB:  PubMed          Journal:  Nat Rev Cancer        ISSN： 1474-175X            Impact factor:   60.716


  9 in total

1.  EPAS1 mRNA in plasma from colorectal cancer patients is associated with poor outcome in advanced stages.

Authors:  N Mohammed; M Rodriguez; V Garcia; J M Garcia; G Dominguez; C Peña; M Herrera; I Gomez; R Diaz; B Soldevilla; A Herrera; J Silva; F Bonilla
Journal:  Oncol Lett       Date:  2011-04-28       Impact factor: 2.967

2.  Glucocorticoid receptor (GR) immunohistochemical expression is correlated with cell cycle-related molecules in human colon cancer.

Authors:  Stamatios Theocharis; Gregorios Kouraklis; Alexandra Margeli; Emmanuel Agapitos; Sotirios Ninos; Gabriel Karatzas; Antonios Koutselinis
Journal:  Dig Dis Sci       Date:  2003-09       Impact factor: 3.199

Review 3.  Referring patients to nurses: outcomes and evaluation of a nurse flexible sigmoidoscopy training program for colorectal cancer screening.

Authors:  Mark J Dobrow; Mary Anne Cooper; Karen Gayman; Jason Pennington; Joanne Matthews; Linda Rabeneck
Journal:  Can J Gastroenterol       Date:  2007-05       Impact factor: 3.522

4.  Understanding non-compliance to colorectal cancer screening: a case control study, nested in a randomised trial [ISRCTN83029072].

Authors:  Paolo Giorgi Rossi; Antonio Federici; Francesco Bartolozzi; Sara Farchi; Piero Borgia; Gabriella Guasticchi
Journal:  BMC Public Health       Date:  2005-12-22       Impact factor: 3.295

5.  Upregulated expression of human neutrophil peptides 1, 2 and 3 (HNP 1-3) in colon cancer serum and tumours: a biomarker study.

Authors:  Jakob Albrethsen; Rikke Bøgebo; Steen Gammeltoft; Jesper Olsen; Benny Winther; Hans Raskov
Journal:  BMC Cancer       Date:  2005-01-19       Impact factor: 4.430

6.  Clinical significance of frizzled homolog 3 protein in colorectal cancer patients.

Authors:  Sze Chuen Cesar Wong; Catherine Wan He; Charles Ming Lok Chan; Amanda Kit Ching Chan; Heong Ting Wong; Moon Tong Cheung; Lewis Lai Yin Luk; Thomas Chi Chuen Au; Man Kin Chiu; Brigette Buig Yue Ma; Anthony Tak Cheung Chan
Journal:  PLoS One       Date:  2013-11-08       Impact factor: 3.240

Review 7.  Flavonoids and Wnt/β-catenin signaling: potential role in colorectal cancer therapies.

Authors:  Nathália G Amado; Danilo Predes; Marcela M Moreno; Igor O Carvalho; Fábio A Mendes; José G Abreu
Journal:  Int J Mol Sci       Date:  2014-07-08       Impact factor: 5.923

Review 8.  Peptide-Based Treatment: A Promising Cancer Therapy.

Authors:  Yu-Feng Xiao; Meng-Meng Jie; Bo-Sheng Li; Chang-Jiang Hu; Rui Xie; Bo Tang; Shi-Ming Yang
Journal:  J Immunol Res       Date:  2015-10-19       Impact factor: 4.818

9.  Hotspot KRAS exon 2 mutations in CD166 positive colorectal cancer and colorectal adenoma cells.

Authors:  Hung Lai Wong; Lawrence Po Wah Ng; Su Pin Koh; Lawrence Wing Chi Chan; Evelyn Yin Kwan Wong; Vivian Weiwen Xue; Hin Fung Andy Tsang; Amanda Kit Ching Chan; Ka Yue Chiu; Wah Cheuk; Sze Chuen Cesar Wong
Journal:  Oncotarget       Date:  2018-04-17
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.